Every 8-K that SPRBD (SPRBD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SPRBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRBD filings page.
Spruce Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026 in virtual format. As of the March 24, 2026 record date, 1,372,278 common shares were outstanding, and 903,893 shares, or about 65.86%, were represented, establishing a quorum.
Stockholders elected three Class III directors—Michael Grey, Camilla V. Simpson and Javier Szwarcberg—to serve until the 2029 annual meeting. They also ratified BDO USA, P.C. as independent auditor for the year ending December 31, 2026 and approved, on an advisory basis, the compensation of named executive officers.
In addition, stockholders indicated a preference for holding an advisory vote on executive compensation every year. The company plans to include an annual, non-binding say‑on‑pay vote in its proxy materials until the next required frequency vote, which must occur no later than the 2032 annual meeting.
Spruce Biosciences reported a first quarter 2026 net loss of $12.3 million, or $(8.94) per share, improving from a $14.0 million loss a year earlier as total operating expenses fell to $12.0 million from $14.5 million on lower R&D spending.
Cash and cash equivalents were $54.1 million as of March 31, 2026 and approximately $107.3 million as of April 30, 2026, supported by a $69.0 million underwritten equity offering and a term loan facility of up to $50.0 million. The company expects this liquidity, together with the April financing, to fund planned operations and debt obligations into the second half of 2027 as it advances its lead therapy TA‑ERT toward a planned BLA submission in the fourth quarter of 2026.
Spruce Biosciences terminated its collaboration and license agreement with Kaken Pharmaceutical for tildacerfont in Japan, effective March 31, 2026, eliminating rights to up to approximately $65.0 million in potential milestone payments and future royalties, though no early termination penalties apply.
The company reported full-year 2025 net loss of $39.0 million, improved from $53.0 million in 2024, as total operating expenses fell to $36.5 million from $61.1 million, driven by ending tildacerfont development and focusing on tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B.
Cash and cash equivalents were $48.9 million as of December 31, 2025, and a loan facility with Avenue Capital provides up to $50 million, including an initial funded tranche of $15 million. Positive FDA Type B meetings support a planned biologics license application for TA-ERT in the fourth quarter of 2026, and new commercial and development leaders were added ahead of a potential launch.